Skip to main content

Table 2 Suppression of p21cip1/waf1 in EBV+ Hodgkin lymphoma is associated with a worse prognosis

From: EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis

 

EBV-

EBV+

p

Clinical Manifestation

   

n

68

26

 

age

34

44

0.18

sex

33:35

19:7

0.04

stage, I&II

72%

50%

0.09

LDH

459

544

0.08

ABVD

70%

58%

0.32

Primary refractory

9% (6/68)

38% (10/26)

0.002

2-year OS

98%

68%

<0.001

2-year DFS

77%

45%

0.002

Biological markers

   

p21 cip1/waf1

76%

44%

<0.001

active caspase 3

22%

4%

<0.001

Ki67

54%

52%

0.80

  1. From top to bottom, the rows which show clinical manifestation are: number of cases, median age in years, sex ratio in male: female, percentage of cases in stages I & II, median LDH (lactate dehydrogenase, normal at 230-460 U/L), percentage of cases initially treated with ABVD (Adriamycin, Bleomycin, Vinblastine, & Dacarbazine), percentage of primary refractory cases, estimated 2-year overall survival rate, and 2-year disease-free survival rate. The rows which show biological markers are: median percentage of Reed-Sternberg cells that were positive for p21cip1/waf1, active caspase 3, and Ki67.
Back to article page

Molecular Cancer

ISSN: 1476-4598